These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 7469121)

  • 1. Plethysmographic registration of volume changes in a hand vein. Effects of serotonin and of a specific antagonist.
    Jageneau AH; Hörig C; Loots W; Symoens J
    Angiology; 1980 Dec; 31(12):828-32. PubMed ID: 7469121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Demonstration of alpha-adrenoceptor antagonism by the 5HT2 antagonist, ketanserin (R49945), in sheep.
    Nelson MA; Coghlan JP; Denton DA; Mills EH; Spence CD; Whitworth JA; Scoggins BA
    Clin Exp Pharmacol Physiol; 1984; 11(6):597-604. PubMed ID: 6152610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular effects of ketanserin in closed-chest anesthetized dogs.
    van de Water A; Wouters L; Xhonneux R; Reneman S
    Arch Int Pharmacodyn Ther; 1985 Jun; 275(2):267-78. PubMed ID: 3161481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Three distinct subtypes of serotonergic receptors mediate the triphasic blood pressure response to serotonin in rats.
    Kalkman HO; Engel G; Hoyer D
    J Hypertens Suppl; 1984 Dec; 2(3):S143-5. PubMed ID: 6599662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of blood pressure ratio by Doppler velocimetry and by plethysmography during treatment with ketanserin, a 5-HT2 receptor antagonist: a measure of improved collateral and microcirculatory flow.
    De Cree J; Leempoels J; Geukens H; Verhaegen H
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S92-4. PubMed ID: 2412069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selectivity of calcium antagonism and serotonin antagonism with respect to venous and arterial tissues.
    Van Nueten JM; Vanhoutte PM
    Angiology; 1981 Jul; 32(7):476-84. PubMed ID: 7247071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ketanserin and alpha 1-adrenergic antagonism in humans.
    Zabludowski JR; Ball SG; Robertson JI
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S123-5. PubMed ID: 2412032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of serotonin and its antagonist ketanserin on pial vessels.
    Auer LM; Leber K; Sayama I
    J Cereb Blood Flow Metab; 1985 Dec; 5(4):517-22. PubMed ID: 2932453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular effects of ketanserin in conscious rabbits.
    Takata M; Zhang X; Sugimoto T; Ikeda K; Tomoda F; Mikawa M; Iida H; Mizumura Y
    Jpn Heart J; 1986 Jan; 27(1):95-106. PubMed ID: 2941601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there alpha-adrenergic blockade and/or serotonergic blockade during chronic ketanserin treatment?
    Ball SG; Robertson JI
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S120-2. PubMed ID: 2412031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of ketanserin on phenylephrine-dependent changes in splanchnic hemodynamics and systemic blood pressure in healthy subjects.
    Gasic S; Eichler HG; Korn A
    J Cardiovasc Pharmacol; 1985; 7(2):219-23. PubMed ID: 2581071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoration of post-thrombotic peripheral collateral circulation in the cat by ketanserin, a selective 5-HT2-receptor antagonist.
    Nevelsteen A; De Clerck F; Loots W; De Gryse A
    Arch Int Pharmacodyn Ther; 1984 Aug; 270(2):268-79. PubMed ID: 6486973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antihypertensive properties of ketanserin (R 41 468).
    Vanhoutte PM; Van Nueten JM; Symoens J; Janssen PA
    Fed Proc; 1983 Feb; 42(2):182-5. PubMed ID: 6295821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does acute serotonergic type-2 antagonism reduce blood pressure? Comparative effects of single doses of ritanserin and ketanserin in essential hypertension.
    Hosie J; Stott DJ; Robertson JI; Ball SG
    J Cardiovasc Pharmacol; 1987; 10 Suppl 3():S86-8. PubMed ID: 2446081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors.
    Van Nueten JM; Janssen PA; Van Beek J; Xhonneux R; Verbeuren TJ; Vanhoutte PM
    J Pharmacol Exp Ther; 1981 Jul; 218(1):217-30. PubMed ID: 6113280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serotonin and the heart: effects of ketanserin on myocardial function, heart rate, and arrhythmias.
    Saman S; Thandroyen F; Opie LH
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S70-5. PubMed ID: 2412064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonin-induced blood flow changes in the rat hindlegs after unilateral ligation of the femoral artery. Inhibition by the S2 receptor antagonist ketanserin.
    Verheyen A; Vlaminckx E; Lauwers F; Van Den Broeck C; Wouters L
    Arch Int Pharmacodyn Ther; 1984 Aug; 270(2):280-98. PubMed ID: 6486974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The specificity of ketanserin in the inhibition of serotonin-induced steroidogenesis in the rat adrenal zona glomerulosa.
    Williams BC; Shaikh S; Edwards CR
    J Hypertens Suppl; 1984 Dec; 2(3):S559-61. PubMed ID: 6100754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serotonin as a modulator of skeletal muscle oxygenation: effects of ketanserin and ritanserin on oxygen pressure distributions.
    Thorborg P; Lund N
    Int J Microcirc Clin Exp; 1989 Apr; 8(2):191-203. PubMed ID: 2499554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of a new serotonin receptor antagonist (ketanserin) on lower urinary tract function in patients with prostatism.
    Hørby-Petersen J; Schmidt PF; Meyhoff HH; Frimodt-Møller C; Mathiesen FR
    J Urol; 1985 Jun; 133(6):1094-8. PubMed ID: 2582152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.